Lawsuits allege GLP-1s cause serious harm, but frequency is unclear
Ongoing lawsuits are targeting manufacturers of GLP-1 receptor agonists, alleging that popular medications like Ozempic can cause severe, life-altering conditions such as non-arteritic anterior ischemic optic neuropathy (NAION), which leads to blindness. Patients and their families claim that drug companies failed to provide adequate warnings about these potential risks. While some observational studies have suggested a correlation between semaglutide use and an increased risk of NAION, medical groups emphasize that correlation does not equal causation. Subsequent studies and professional societies have cast doubt on whether the drugs directly cause the condition, highlighting a critical lack of definitive data regarding how often such severe adverse effects actually occur.